Articles published by Circle Pharma, Inc.

Circle Pharma Announces Participation in November Investor Conferences

November 04, 2026

Circle Pharma Strengthens Leadership Team with Promotion of Marie Evangelista, Ph.D., to Chief Scientific Officer and Addition of Mary Ellen Sillivos as SVP and Head of Human Resources

September 28, 2026

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development

September 16, 2026

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026

March 18, 2026

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors

March 12, 2026

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma to Participate in Upcoming Investor Conferences

February 17, 2026

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program

December 17, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer

December 01, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Participation in Upcoming Investor Conferences

November 04, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Appoints Rob Lauzen as Chief Financial Officer

November 03, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

September 25, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma to Participate in Upcoming Investor Conferences

September 02, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition

August 20, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

June 16, 2025

From Circle Pharma, Inc.

Via Business Wire

Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting

May 27, 2025

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

October 23, 2024

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors

October 15, 2024

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies

September 16, 2024

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer

September 09, 2024

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies

September 03, 2024

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 09, 2023

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma strengthens its executive leadership team with two senior appointments in Clinical Development

July 26, 2023

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

April 19, 2023

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

December 15, 2022

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Appoints Paul Park, MBA, as its Chief Business Officer

July 26, 2022

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting

April 11, 2022

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Appoints Evelyn Wang, PhD as its Vice President, Translational Medicine

July 12, 2021

From Circle Pharma, Inc.

Via Business Wire

Circle Pharma Raises $66 Million in Series C Financing

June 16, 2021

From Circle Pharma, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.